PFE ▼ -0.1% - Pfizer Inc.
$PFE - Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
27-OCT-2026 06:56 AM ET
Share this post
More filings for $PFE
PFE ▼ -0.9% - Pfizer Inc.Oct 26, 2026PFE ▼ -1.3% - Pfizer Inc.Oct 24, 2026PFE ▲ +0.6% - Pfizer Inc.Oct 14, 2026PFE ▲ +2.3% - Pfizer Inc.Oct 7, 2026PFE ▲ +2.1% - Pfizer Inc.Oct 7, 2026PFE ▲ +0.3% - Pfizer Inc.Oct 6, 2026
View full $PFE filing history →💬 Comments
Loading comments…
Leave a comment